Study details
Enrolling now
First-in-human Study of [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
University of California, Davis
NCT IDNCT04665947ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
30
Study length
about 5.5 years
Ages
18+
Locations
1 site in CA
What this study is about
Researchers are testing the safety and effectiveness of a new treatment, [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G, in people with locally advanced or metastatic pancreatic cancer. The trial will last for about 20 months.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: [68Ga]Ga DOTA-5G PET/CT imaging
Body systems
Oncology